Anika Therapeutics
ANIK
114 hedge funds and large institutions have $335M invested in Anika Therapeutics in 2024 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 40 increasing their positions, 49 reducing their positions, and 14 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
1% less capital invested
Capital invested by funds: $340M → $335M (-$5.1M)
2.46% less ownership
Funds ownership: 91.54% → 89.09% (-2.5%)
5% less funds holding
Funds holding: 120 → 114 (-6)
18% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 49
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
46% less call options, than puts
Call options by funds: $68K | Put options by funds: $127K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
+$2.77M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.71M |
| 3 |
GC
Globeflex Capital
San Diego,
California
|
+$1.71M |
| 4 |
TI
Trigran Investments
Northbrook,
Illinois
|
+$1.65M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.18M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$2.49M |
| 3 |
Millennium Management
New York
|
-$2.21M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.57M |
| 5 |
CM
Capital Management
Glen Allen,
Virginia
|
-$918K |
ANIK Hedge Fund Activity: Q2 2024 in Review
114 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q2 2024, worth a combined $335M — down 1.5% from $340M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ANIK and 10 opened new positions — a net loss of 4 holders — while 49 trimmed existing stakes and 40 added.
The largest buyer was Segall Bryant & Hamill, opening a new position worth an estimated $2.77M. The largest seller was Morgan Stanley, cutting an estimated $5.18M.
- 114 institutional investors held Anika Therapeutics (ANIK) as of Q2 2024, down from 120 in Q1 2024.
- Funds reported $335M of Anika Therapeutics stock for Q2 2024, down 1.5% quarter-over-quarter.
- 10 funds opened new Anika Therapeutics positions in Q2 2024 and 14 closed out, a net change of -4 holders.
- The largest Anika Therapeutics buyer in Q2 2024 was Segall Bryant & Hamill, an estimated $2.77M added.
- The largest Anika Therapeutics seller in Q2 2024 was Morgan Stanley, an estimated $5.18M sold.
Based on aggregated 13F filings for Q2 2024.